ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
LIC sold 20,242,068 Zydus Lifesciences shares via market sale, cutting its stake from 5.21 percent to 3.18 percent. Non-promoter SAST disclosure covering 28.08.2025 to 05.11.2026.
Zydus Lifesciences' subsidiary presented Phase 2b trial data for investigational saroglitazar in MASH at AASLD 2026. The drug showed higher steatohepatitis resolution than placebo, but its safety and effectiveness for this use are not yet established.
Consolidated revenue ₹7,910 Cr (+29% YoY), EBITDA margin 24%, net profit ₹930 Cr. Growth partly acquisition-led. Saroglitazar launch spend is heavy and the US launch is targeted for March 2027.
Zydus Lifesciences reported Q2 FY27 revenue of Rs. 79,096 mn, up 29% y-o-y. H1 net profit was Rs. 18,859 mn, down 31%.
Q2 FY27 revenue Rs 7,910 Cr (+29% YoY), EBITDA Rs 1,895 Cr at 24.0% margin, reported PAT Rs 926 Cr (-26.6% YoY). Branded India and North America drove growth; FX and D&A weighed on profit.
Zydus Lifesciences board approved appointment of Walker Chandiok & Co LLP as statutory auditors for a five-year term. This follows mandatory rotation of outgoing auditor Deloitte Haskins and Sells LLP.
Zydus Lifesciences Ltd reported revenue from operations of ₹7,910 Cr (+29.2% YoY) and net profit of ₹925.5 Cr (-26.6% YoY) for Q2 FY27.
Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.
Zydus Lifesciences completed acquisition of Sterling Biotech's API business for Rs. 167 Crore. The slump sale of fermentation-based API products strengthens its manufacturing portfolio.
Zydus Lifesciences completed its acquisition of Sterling Biotech's API business under a September 2024 Business Transfer Agreement. No transaction value was disclosed in this filing.
Zydus Lifesciences announced the resignation of Dr. Amrut Naik, President of International Markets, effective 7 November 2026. Mr. Christoph Stoller has been appointed to the same senior management role from 2 November 2026.
Zydus Lifesciences' division Zylidac Bio partnered with Prolific Machines to scale their next-generation biologics manufacturing platform for GMP production.
Zydus Lifesciences received USFDA approval for its Estradiol-Levonorgestrel Transdermal System ANDA, designated as a CGT. The product is eligible for 180-day exclusivity upon first commercial marketing.
Zydus Lifesciences intimated a board meeting on 4 Nov 2026 to approve unaudited Q1/H1 FY27 results. Trading window remains closed until 6 Nov 2026.
Zydus Lifesciences Limited has been assigned an ESG rating of 71 by NSRAL for the financial year 2026. This unsolicited rating reflects the company's sustainability performance.
Zydus' JV with Sunshine Healthcare signed a BOI agreement to establish a pharma plant in Sri Lanka. Investment exceeds USD 20 million (~₹190 Cr), targeting 2028.